title: Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
abstract: In an effort to maximize both local-regional and systemic drug exposure to tumor in the peritoneal cavity, a phase I study was conducted that examined the simultaneous daily intraperitoneal (IP) and continuous intravenous infusion (CVI) of fluorouracil (5-FU) to 32 patients with refractory cancer. IP 5-FU administered at 1,000 mg/d with concurrent 5-FU by CVI at 1,000 mg/m2/d for four consecutive days was well tolerated. One patient with a primary gastrointestinal (GI) malignancy with minimal volume disease experienced a surgically defined complete remission. In theory, this regimen may demonstrate clinical utility as an adjuvant treatment of certain GI malignancies. Future studies are planned in this clinical setting.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: B
authors.initials: B
authors.lastname: Reichman
authors.forename: M
authors.initials: M
authors.lastname: Markman
authors.forename: T
authors.initials: T
authors.lastname: Hakes
authors.forename: N
authors.initials: N
authors.lastname: Kemeny
authors.forename: D
authors.initials: D
authors.lastname: Kelsen
authors.forename: W
authors.initials: W
authors.lastname: Hoskins
authors.forename: S
authors.initials: S
authors.lastname: Rubin
authors.forename: J L
authors.initials: JL
authors.lastname: Lewis
mesh_terms: D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
chemical_list: D005472:Fluorouracil